241 related articles for article (PubMed ID: 31312661)
21. Breast Cancer Neoantigens Can Induce CD8
Zhang X; Kim S; Hundal J; Herndon JM; Li S; Petti AA; Soysal SD; Li L; McLellan MD; Hoog J; Primeau T; Myers N; Vickery TL; Sturmoski M; Hagemann IS; Miller CA; Ellis MJ; Mardis ER; Hansen T; Fleming TP; Goedegebuure SP; Gillanders WE
Cancer Immunol Res; 2017 Jul; 5(7):516-523. PubMed ID: 28619968
[TBL] [Abstract][Full Text] [Related]
22. Targeting neoantigens to augment antitumour immunity.
Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
[TBL] [Abstract][Full Text] [Related]
23. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
24. Exome Sequencing to Predict Neoantigens in Melanoma.
Pritchard AL; Burel JG; Neller MA; Hayward NK; Lopez JA; Fatho M; Lennerz V; Wölfel T; Schmidt CW
Cancer Immunol Res; 2015 Sep; 3(9):992-8. PubMed ID: 26048577
[TBL] [Abstract][Full Text] [Related]
25. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
Okada M; Shimizu K; Fujii SI
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
[TBL] [Abstract][Full Text] [Related]
26. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
[TBL] [Abstract][Full Text] [Related]
27. Neoantigens in cancer immunotherapy.
Schumacher TN; Schreiber RD
Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
[TBL] [Abstract][Full Text] [Related]
28. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.
Löffler MW; Mohr C; Bichmann L; Freudenmann LK; Walzer M; Schroeder CM; Trautwein N; Hilke FJ; Zinser RS; Mühlenbruch L; Kowalewski DJ; Schuster H; Sturm M; Matthes J; Riess O; Czemmel S; Nahnsen S; Königsrainer I; Thiel K; Nadalin S; Beckert S; Bösmüller H; Fend F; Velic A; Maček B; Haen SP; Buonaguro L; Kohlbacher O; Stevanović S; Königsrainer A; ; Rammensee HG
Genome Med; 2019 Apr; 11(1):28. PubMed ID: 31039795
[TBL] [Abstract][Full Text] [Related]
29. Neoantigens as potential vaccines in hepatocellular carcinoma.
Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Aparicio B; Egea J; Tamayo-Uria I; Hervás-Stubbs S; García-Balduz J; Castro C; Iñarrairaegui M; Tagliamonte M; Mauriello A; Cavalluzzo B; Buonaguro L; Rohrer C; Heim K; Tauber C; Hofmann M; Thimme R; Sangro B; Sarobe P
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193931
[TBL] [Abstract][Full Text] [Related]
30. Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer.
Liang H; Xu Y; Chen M; Zhao J; Zhong W; Liu X; Gao X; Li S; Li J; Guo C; Jia H; Wang M
Front Immunol; 2021; 12():749461. PubMed ID: 35356154
[TBL] [Abstract][Full Text] [Related]
31. Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy.
Blaeschke F; Paul MC; Schuhmann MU; Rabsteyn A; Schroeder C; Casadei N; Matthes J; Mohr C; Lotfi R; Wagner B; Kaeuferle T; Feucht J; Willier S; Handgretinger R; StevanoviĆ S; Lang P; Feuchtinger T
Cytotherapy; 2019 Sep; 21(9):973-986. PubMed ID: 31351799
[TBL] [Abstract][Full Text] [Related]
32. TSNAD and TSNAdb: The Useful Toolkit for Clinical Application of Tumor-Specific Neoantigens.
Wu J; Zhou Z
Methods Mol Biol; 2023; 2673():167-174. PubMed ID: 37258913
[TBL] [Abstract][Full Text] [Related]
33. Identification of novel genes by whole-exome sequencing can improve gastric cancer precision oncology.
Lianos GD; Glantzounis GK; Bali CD; Katsios C; Roukos DH
Future Oncol; 2017 Apr; 13(10):883-892. PubMed ID: 27897040
[TBL] [Abstract][Full Text] [Related]
34. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
Front Immunol; 2021; 12():644637. PubMed ID: 33927717
[TBL] [Abstract][Full Text] [Related]
35. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.
Lennerz V; Fatho M; Gentilini C; Frye RA; Lifke A; Ferel D; Wölfel C; Huber C; Wölfel T
Proc Natl Acad Sci U S A; 2005 Nov; 102(44):16013-8. PubMed ID: 16247014
[TBL] [Abstract][Full Text] [Related]
36. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer.
Yin Q; Tang J; Zhu X
Brief Funct Genomics; 2019 Mar; 18(2):119-128. PubMed ID: 29982317
[TBL] [Abstract][Full Text] [Related]
37. Targeting public neoantigens for cancer immunotherapy.
Pearlman AH; Hwang MS; Konig MF; Hsiue EH; Douglass J; DiNapoli SR; Mog BJ; Bettegowda C; Pardoll DM; Gabelli SB; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S
Nat Cancer; 2021 May; 2(5):487-497. PubMed ID: 34676374
[TBL] [Abstract][Full Text] [Related]
38. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
39. [Cancer immunotherapy targeting neoantigens derived from tumor-specific gene mutations].
Sasada T
Nihon Rinsho; 2017 Feb; 75(2):189-195. PubMed ID: 30562851
[TBL] [Abstract][Full Text] [Related]
40. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
